Effi Ahoua B, Aman N'guiessan A, Koui Baumaney S, Koffi Kouadio D, Traore Zie C, Kouyate Mohamed
Department of Anatomic Pathology, School of Medicine, Alassane Ouattara University, Bouake, Ivory Coast E-mail :
Asian Pac J Cancer Prev. 2016;17(4):1973-8. doi: 10.7314/apjcp.2016.17.4.1973.
Breast cancer is a heterogeneous disease that represents a major public health problem. The immunohistochemical determination of breast cancer subtypes with regard to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) status can contribute to improved selection of therapy and patientcare. The purpose of this study was to determine the prevalence of the molecular breast cancer subtypes and to assess their associations with classical clinicopathologic parameters for better therapeutic decisions in women with breast cancer in the Ivory Coast.
Formalin- fixed and paraffin-embedded blocks of patients diagnosed with primary breast carcinoma were subjected to immunohistochemical assay for the assessment of ER/RP and HER2 expression. The one-way analysis of variance evaluated the difference between breast cancer subtypes and mean age of patients. The Chi-square Test was used to compare standard clinicopathologic prognostic parameters with tumor subtypes.
Among 302 patients, 57% were premenopausal and 43% were postmenopausal. The invasive ductal carcinoma not otherwise specified (IDC NOS) (82.8%) was the most frequent histological type, and the tumor grade 2 (56%) was predominant followed by grade 3 (20.9%). The proportion of positivity of ER, PR, and HER2 was 56%, 49%, and 15.6%, respectively. Half of patients of this study (51.6%) had luminal A breast tumor type followed by TN (32.1%). Other subtypes were luminal B (10.1% ) and non-luminal HER2+ (6.3%).
The findings of the present study are in line with the literature and should assist in management of breast cancer in our country.
乳腺癌是一种异质性疾病，是一个重大的公共卫生问题。通过免疫组织化学方法确定乳腺癌雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体（HER2）状态的亚型，有助于优化治疗选择和患者护理。本研究旨在确定科特迪瓦乳腺癌分子亚型的患病率，并评估它们与经典临床病理参数的相关性，以便为乳腺癌女性患者做出更好的治疗决策。
对诊断为原发性乳腺癌患者的福尔马林固定石蜡包埋组织块进行免疫组织化学分析，以评估ER/PR和HER2的表达。单因素方差分析评估乳腺癌亚型与患者平均年龄之间的差异。卡方检验用于比较标准临床病理预后参数与肿瘤亚型。
在302例患者中，57%为绝经前患者，43%为绝经后患者。最常见的组织学类型是未特殊说明的浸润性导管癌（IDC NOS）（82.8%），肿瘤2级（56%）最为常见，其次是3级（20.9%）。ER、PR和HER2的阳性率分别为56%、49%和15.6%。本研究中一半患者（51.6%）为腔面A型乳腺癌，其次是三阴型（TN）（32.1%）。其他亚型为腔面B型（10.1%）和非腔面HER2过表达型（6.3%）。
本研究结果与文献一致，应有助于我国乳腺癌的管理。
